Project Term
–
Project Summary
In May 2023, LLS made an equity investment in Dimericon to "Support development of dimericons (crosslinked helix dimers) for blood cancers."
Dimericon is a private biotech company focused on exploring crosslinked helix dimers (Dimericons) as therapeutics and templates for small molecule development. Dimericon’s technology targets hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The Seed round of financing will support preclinical studies to further develop the current cFLIP inhibitor lead compound, DMRX1004, to be an IND ready clinical candidate in hematological malignancies.
Lay Abstract
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio
Program
